Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ADXN
Addex Therapeutics Ltd. Sponsored ADR (ADXN) EV/Sales
As of 16 October 2026, Addex Therapeutics Ltd. Sponsored ADR (ADXN) trades at a EV/Sales of 18.3×. Over the past ten years it has ranged from −4.9× (December 2022) to 58.7× (April 2026); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 48.9× | 1,063.37% |
| FY2024 | 4.2× | — |
| FY2023 | −0.2× | — |
| FY2022 | −1.5× | — |
| FY2021 | 4.2× | (59.31%) |
| FY2020 | 10.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 48.9× | 82.36% |
| Sep 2025 | 26.8× | 537.97% |
| Dec 2024 | 4.2× | (34.96%) |
| Sep 2024 | 6.5× | 174.40% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EOCN Eocene Ltd. compare | −3.0× |
| APVO Aptevo Therapeutics Inc. compare | −0.3× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 2.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | 18.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)